Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
Zacks Investment Research on MSN
Will Keytruda continue to aid Merck's top line in Q4 earnings?
A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback